{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:24:57Z","timestamp":1782512697479,"version":"3.54.5"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejim.2012.10.011","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T06:01:47Z","timestamp":1353477707000},"page":"20-26","source":"Crossref","is-referenced-by-count":67,"title":["Metformin: The hidden chronicles of a magic drug"],"prefix":"10.1016","volume":"24","author":[{"given":"Khalid","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir Ali","family":"Rahimnajjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2012.10.011_bb0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Drug therapy\u2014metformin","volume":"334","author":"Wood","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0010","first-page":"89","article-title":"Metformin \u2014 a review of its metabolic effects","volume":"6","author":"Cusi","year":"1998","journal-title":"Diabetes Rev"},{"key":"10.1016\/j.ejim.2012.10.011_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/157339906777950651","article-title":"Metformin beyond diabetes: new life for an old drug","volume":"2","author":"Rotella","year":"2006","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.ejim.2012.10.011_bb0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","article-title":"Metformin in cancer therapy: a new perspective for an old antidiabetic drug?","volume":"9","author":"Ben Sahra","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejim.2012.10.011_bb0025","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/diabetes.51.7.2074","article-title":"Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes","volume":"51","author":"Musi","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2012.10.011_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1900\/RDS.2009.6.13","article-title":"Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations","volume":"6","author":"Gruzman","year":"2009","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.ejim.2012.10.011_bb0035","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2012.10.011_bb0040","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.bbabio.2012.02.019","article-title":"Fatty acids revert the inhibition of respiration caused by the antidiabetic drug metformin to facilitate their mitochondrial \u03b2-oxidation","volume":"1817","author":"Gonz\u00e1lez-Barroso","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejim.2012.10.011_bb0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ejim.2012.10.011_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejim.2012.10.011_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000327151","article-title":"Use of metformin in patients with kidney and cardiovascular diseases","volume":"1","author":"Klachko","year":"2011","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0060","doi-asserted-by":"crossref","first-page":"e1771","DOI":"10.1136\/bmj.e1771","article-title":"Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses","volume":"344","author":"Hemmingsen","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2012.10.011_bb0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1262-3636(03)72786-4","article-title":"Improving survival with metformin: the evidence base today","volume":"29","author":"Scarpello","year":"2003","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ejim.2012.10.011_bb0070","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2012.10.011_bb0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","article-title":"The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial","volume":"142","author":"Orchard","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0080","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1161\/ATVBAHA.111.241893","article-title":"Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program","volume":"32","author":"Goldberg","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0085","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10year follow up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Diabetes Prevention Program Research Group","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2012.10.011_bb0090","first-page":"1","article-title":"Metformin monotherapy for type 2 diabetes mellitus","volume":"1","author":"Saenz","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2012.10.011_bb0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1463-1326.2006.00611.x","article-title":"Short-term effects of metformin in type 2 diabetes","volume":"9","author":"Eriksson","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2012.10.011_bb0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2005.00497.x","article-title":"Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones","volume":"7","author":"Bailey","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2012.10.011_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.diabres.2007.02.012","article-title":"Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients","volume":"1","author":"Ohira","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejim.2012.10.011_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","article-title":"The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review","volume":"256","author":"Wulffele","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2012.10.011_bb0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2334-10-183","article-title":"The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials","volume":"10","author":"Sheth","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ejim.2012.10.011_bb0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","article-title":"Metformin for treatment of antipsychotic induced weight gain: a randomized, placebo-controlled study","volume":"138","author":"Wang","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.ejim.2012.10.011_bb0130","first-page":"2434","article-title":"A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain","volume":"85","author":"Asuncion","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2012.10.011_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Fauser","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejim.2012.10.011_bb0140","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2012.10.011_bb0145","first-page":"27","article-title":"PCOS and metformin: from pharmacology to clinical use for women's health","volume":"18","author":"Genazzani","year":"2012","journal-title":"Arch Perinat Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0150","doi-asserted-by":"crossref","DOI":"10.1210\/er.2012-1003","article-title":"Cardiometabolic aspects of the polycystic ovary syndrome","author":"Randeva","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejim.2012.10.011_bb0155","first-page":"25","article-title":"Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin","volume":"37","author":"Weickert","year":"2012","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/humupd\/dmm026","article-title":"The role of metformin in polycystic ovary syndrome: a systematic review","volume":"13","author":"Moll","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejim.2012.10.011_bb0165","first-page":"139","article-title":"Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation","volume":"85","author":"Moghetti","year":"2000","journal-title":"JCEM"},{"key":"10.1016\/j.ejim.2012.10.011_bb0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/humupd\/dmn015","article-title":"Follicle dynamics and anovulation in polycystic ovary syndrome","volume":"14","author":"Franks","year":"2008","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejim.2012.10.011_bb0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1210\/jc.2007-1650","article-title":"Cell survival and proliferation are altered in polycystic ovary syndrome","volume":"93","author":"Das","year":"2008","journal-title":"JCEM"},{"key":"10.1016\/j.ejim.2012.10.011_bb0180","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1210\/mend.11.13.0032","article-title":"Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary","volume":"11","author":"Zhou","year":"1997","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0185","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2011-3061","article-title":"Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial","volume":"97","author":"Morin-Papunen","year":"2012","journal-title":"JCEM"},{"key":"10.1016\/j.ejim.2012.10.011_bb0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1479164109336050","article-title":"Long term effect of metformin on metabolic parameters in the polycystic ovary syndrome","volume":"6","author":"Cheang","year":"2009","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ejim.2012.10.011_bb0195","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1093\/humrep\/des262","article-title":"Is there a dose\u2013response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study","volume":"27","author":"Fulghesu","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejim.2012.10.011_bb0200","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.3748\/wjg.v12.i48.7826","article-title":"Insulin sensitizers in treatment of non-alcoholic fatty liver disease: systematic review","volume":"12","author":"Tapia-Chavez","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1024\/0300-9831\/a000086","article-title":"Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescent with fatty liver","volume":"81","author":"Akcam","year":"2011","journal-title":"Int J Vitam Nutr Res"},{"key":"10.1016\/j.ejim.2012.10.011_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/716404","article-title":"The role of metformin in the management of NAFLD","author":"Mazza","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.ejim.2012.10.011_bb0215","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2337\/diacare.28.10.2585","article-title":"Metformin and heart failure: innocent until proven guilty","volume":"28","author":"Inzucchi","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2012.10.011_bb0220","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2337\/db11-1132","article-title":"Metformin prevents the development of chronic heart failure in the SHHF rat model","volume":"61","author":"Cittadini","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2012.10.011_bb0225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.39314.620174.80","article-title":"Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review","volume":"335","author":"Eurich","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2012.10.011_bb0230","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2337\/dc09-2227","article-title":"Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case\u2013control study from the U.K. general practice research database","volume":"33","author":"MacDonald","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2012.10.011_bb0235","doi-asserted-by":"crossref","first-page":"e8758","DOI":"10.1371\/journal.pone.0008758","article-title":"Metformin Induces a dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN-1","volume":"5","author":"Onken","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2012.10.011_bb0240","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","article-title":"Metformin therapy in a transgenic mouse model of Huntington's disease","volume":"411","author":"Ma","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.ejim.2012.10.011_bb0245","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1212\/01.WNL.0000140292.04932.87","article-title":"Hyperinsulinemia and risk of Alzheimer disease","volume":"63","author":"Luchsinger","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejim.2012.10.011_bb0255","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/rej.2011.1238","article-title":"Rapamycin as an antiaging therapeutic? Targeting mammalian target of rapamycin to treat Hutchinson\u2013Gilford progeria and neurodegenerative diseases","volume":"14","author":"Mendelsohn","year":"2011","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.ejim.2012.10.011_bb0260","doi-asserted-by":"crossref","first-page":"348","DOI":"10.18632\/aging.100316","article-title":"Gerosuppressant metformin: less is more","volume":"3","author":"Menendez","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.ejim.2012.10.011_bb0265","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/annrheumdis-2011-200557","article-title":"Autophagy activation by rapamycin reduces severity of experimental osteoarthritis","volume":"71","author":"Caram\u00e9s","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2012.10.011_bb0270","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-012-8314-5","article-title":"The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis","author":"Russo","year":"2012","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0275","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2004-0019","article-title":"The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial","volume":"89","author":"Caballero","year":"2004","journal-title":"JCEM"},{"key":"10.1016\/j.ejim.2012.10.011_bb0280","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.ATV.0000201938.78044.75","article-title":"Metformin inhibits proinflammatory responses and nuclear factor-\u03baB in human vascular wall cells","volume":"26","author":"Isoda","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1124\/jpet.109.164970","article-title":"Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro","volume":"334","author":"Arai","year":"2010","journal-title":"JPET"},{"key":"10.1016\/j.ejim.2012.10.011_bb0290","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1167\/iovs.12-9432","article-title":"Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats","volume":"53","author":"Kalariya","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ejim.2012.10.011_bb0295","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.intimp.2012.01.015","article-title":"Antidiabetic drug metformin alleviates endotoxin-induced fulminant liver injury in mice","volume":"12","author":"Hongmei Yuan","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0300","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/00007890-199457120-00024","article-title":"The direct effect of FK506 and rapamycin on interleukin 1 and immunoglobulin production in vitro","volume":"57","author":"Yoshimura","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.ejim.2012.10.011_bb0305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/cyto.2001.0954","article-title":"CD40 ligation induces macrophage IL-10 and TNF-\u03b1 production: differential use of the PI3K and p42\/44 MAPK-pathways","volume":"16","author":"Foey","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.ejim.2012.10.011_bb0310","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2249.1996.d01-651.x","article-title":"The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast","volume":"104","author":"Migita","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0315","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.1993.tb35855.x","article-title":"Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases","volume":"685","author":"Carlson","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejim.2012.10.011_bb0320","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1074\/jbc.M410480200","article-title":"Akt1\/Akt2 and mammalian target of rapamycin\/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors","volume":"280","author":"Sugatani","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2012.10.011_bb0325","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNF\u03b1 and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ejim.2012.10.011_bb0330","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","article-title":"Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts","volume":"35","author":"Kneissel","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.ejim.2012.10.011_bb0335","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/ard.2007.078808","article-title":"Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study","volume":"67","author":"Bruyn","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2012.10.011_bb0340","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0345","first-page":"re7","article-title":"Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer","author":"Marshall","year":"2006","journal-title":"Sci STKE"},{"key":"10.1016\/j.ejim.2012.10.011_bb0350","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","article-title":"Metformin in cancer therapy: a new perspective for an old antidiabetic drug?","volume":"9","author":"Sahra","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejim.2012.10.011_bb0355","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s002590000367","article-title":"Correlation of Glut-1 glucose transporter expression with [18F] FDG uptake in non-small cell lung cancer","volume":"27","author":"Higashi","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0360","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2012.10.011_bb0365","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2012.10.011_bb0370","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes","volume":"33","author":"Landman","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2012.10.011_bb0375","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2012.10.011_bb0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1055-9965.EPI-10-0817","article-title":"Metformin and incident breast cancer among diabetic women: a population-based case\u2013control study in Denmark","volume":"20","author":"Bosco","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejim.2012.10.011_bb0385","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc09-1791","article-title":"Long-term metformin use is associated with decreased risk of breast cancer","volume":"33","author":"Bodmer","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2012.10.011_bb0390","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2407-11-20","article-title":"Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0395","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2012.10.011_bb0400","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1741-7015-9-33","article-title":"Understanding the benefit of metformin use in cancer treatment","volume":"9","author":"Dowling","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2012.10.011_bb0405","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4161\/cc.11.5.19252","article-title":"Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation","volume":"11","author":"Oliveras-Ferraros","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejim.2012.10.011_bb0410","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/cc.19798","article-title":"Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation","volume":"11","author":"Sikka","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejim.2012.10.011_bb0415","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/1940-6207.CAPR-11-0502","article-title":"Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions","volume":"5","author":"Vitale-Cross","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.ejim.2012.10.011_bb0420","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0016-5085(11)60892-5","article-title":"Chemopreventive potential of metformin in Barrett's esophagus","volume":"140","author":"Faridar","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2012.10.011_bb0430","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/ERC-12-0046","article-title":"Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells","volume":"19","author":"Joanna Klubo-Gwiezdzinska","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0435","doi-asserted-by":"crossref","first-page":"E510","DOI":"10.1210\/jc.2011-1754","article-title":"Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells and potentiates the effect of chemotherapeutic agents","volume":"97","author":"Cheng","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0440","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1053\/gast.2001.23258","article-title":"Prevention of pancreatic cancer induction in hamsters by metformin","volume":"120","author":"Schneider","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2012.10.011_bb0445","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/ajg.2011.483","article-title":"Use of antidiabetic agents and the risk of pancreatic cancer: a case\u2013control analysis","volume":"107","author":"Bodmer","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0450","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","article-title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism","volume":"1","author":"Kahn","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejim.2012.10.011_bb0455","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0002-9440(10)63053-2","article-title":"STK11\/LKB1 Peutz\u2013Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas","volume":"159","author":"Sato","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0460","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1096\/fj.11-192088","article-title":"Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells","volume":"26","author":"Salani","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.ejim.2012.10.011_bb0465","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2012.08.010","article-title":"Metformin does not alter the risk of lung cancer: A Case\u2013control analysis","volume":"78","author":"Bodmer","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0470","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/1471-2407-12-410","article-title":"The effect of metformin and thiazolidinediones use on lung cancer in diabetics","volume":"14","author":"Mazzone","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0475","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/cc.8.1.7499","article-title":"The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells","volume":"8","author":"Vazquez-Martin","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejim.2012.10.011_bb0480","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.26439","article-title":"Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer","volume":"118","author":"Bayraktar","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0485","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/IGC.0b013e3182322834","article-title":"LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells","volume":"22","author":"Cuilan","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0490","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2011.06.038","article-title":"Use of metformin and the risk of ovarian cancer: a case\u2013control analysis","volume":"123","author":"Bodmer","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0495","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.ejim.2012.10.011_bb0500","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/bjc.2012.71","article-title":"Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer","volume":"106","author":"Garrett","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejim.2012.10.011_bb0505","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejim.2012.10.011_bb0510","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation\u2014implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512002841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512002841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T11:02:44Z","timestamp":1594897364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620512002841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0953620512002841"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2012.10.011","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}